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Abstract 
Background: Chronic rhinosinusitis with nasal polyps is characterized by local inflammation and is categorized into 
two subtypes in Japan: eosinophilic chronic rhinosinusitis, and non-eosinophilic chronic rhinosinusitis. The objective 
of this study was to investigate the expression of key transcription factors for Treg and Th1/Th2/Th17 cells, in relation 
to the mRNA expression of representative cytokines in these two subtypes of chronic rhinosinusitis with nasal polyps.
Methods: The expression of forkhead box P3 (FOXP3), T-box transcription factor (T-bet), GATA3, retinoid acid-related 
orphan receptor C (RORc), the suppressive cytokines TGF-β1 and IL-10, and Th1/Th2/Th17 cytokines (IFN-γ, IL-4, IL-5, 
IL-13, IL-17) were analyzed by means of RT-PCR in eosinophilic polyps. Eosinophilic polyps were defined as having an 
eosinophil count of more than 50 per microscopic field (×400 magnification) using five fields located in the subepi-
thelial area of the polyps, while the non-eosinophilic polyps and controls did not fulfill this criteria. The numbers of 
T cells, CD4+ T cells, CD8+ T cells and Treg were histologically counted using sections that were immunostained for 
CD3, CD4, CD8, and FOXP3, respectively.
Results: In eosinophilic polyps, we observed significantly fewer CD4+ T cells and CD8+ T cells, and lower GATA3, 
RORc and IL-10 mRNA expression, but a significantly higher IL-5, and IL-13 mRNA expression compared with controls, 
whereas FOXP3 and T-bet mRNA expression were not significantly different compared with controls. In non-eosino-
philic polyps, FOXP3, IL-10, IL-17A, TGFβ1 and IFNγ mRNA expression was significantly higher compared with controls, 
whereas IL-4, 5 and 13 expression was not significantly different from controls.
Conclusion: We showed a reduction of GATA3 and RORc mRNA, low Treg-related cytokines and elevated Th2 
cytokine levels in eosinophilic chronic rhinosinusitis, whereas we demonstrated the upregulation of Treg cells and 
increases of Th1 and Th17 cytokines in non-eosinophilic chronic rhinosinusitis in the Japanese population. The dif-
ferent mRNA expression profiles of Treg and Th1/Th2/Th17 signature transcription factors and cytokines between 
eosinophilic chronic rhinosinusitis and non-eosinophilic chronic rhinosinusitis suggests heterogeneity in the patho-
genesis of chronic rhinosinusitis with nasal polyps.
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Background
Chronic rhinosinusitis with nasal polyps (CRSwNP) is 
an inflammatory disease that remains difficult to treat 
despite advances in medical and surgical therapy. The 
majority of patients with CRSwNP in the United States 
and Europe have pronounced infiltration of eosinophils 
and expression of interleukin-5 (IL-5) in nasal polyps 
[1]. In contrast, greater heterogeneity in CRSwNP has 
been reported in East Asian countries, such as Japan 
and China. For example, Cao et  al. reported that more 
than half of Chinese CRSwNP patients presented with a 
Th17-dominant, neutrophilic inflammation pattern [2]. 
In a recent study by Shi et  al., they found significantly 
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enhanced mucous metaplasia and tissue remodeling 
in non-ECRS patients in China [3]. More than half 
of CRSwNP cases in Japan do not exhibit eosinophil-
dominant inflammation [4, 5]. In Japan, CRSwNP is 
categorized into two subtypes: eosinophilic chronic rhi-
nosinusitis (ECRS), which is similar to the CRSwNP in 
western countries, and non-eosinophilic chronic rhinosi-
nusitis (non-ECRS), which is characterized by Th1-domi-
nant inflammation [4].
Naive T cells differentiate toward different T-cell sub-
types on the basis of the expression of certain transcrip-
tion factors. T-box transcription factor (T-bet) directs 
lineage commitment toward Th1 cells [6]; GATA-3 
is critical for commitment toward Th2 cells and con-
trols the expression of IL-4 and IL-5 [7, 8]. The balance 
between Th1 and Th2 is controlled by T regulatory (Treg) 
cells [9]. Forkhead box P3 (FOXP3) is essential for Treg 
development, survival, and function [10]. Recent stud-
ies indicate that Treg cells play an important role in the 
expression and regulation of T-cell subtypes in CRSwNP 
both in Asian [11] and Caucasian [12] regions.
Th17 cells are newly identified immune/inflammatory 
cell subsets which are now widely believed to be critical 
for the regulation of various chronic immune diseases 
[13]. Th17 cells are characterized by their preferential 
production of interleukins IL-17A and F and require reti-
noid orphan nuclear receptors (RORc) as a key transcrip-
tion factor for their differentiation in humans [14, 15]. 
IL-17A has been revealed to play a significant role in reg-
ulating inflammation, modulating airway structural cells 
and stimulating innate immunity to mediate neutrophil 
recruitment in asthma and other airway diseases [16]. 
Recently, Xia et  al. reported that IL-17A plays a crucial 
role in stimulating the production of MUC5AC and gob-
let cell hyperplasia through the act1-mediated signaling 
pathway, and that IL-17A may be a promising therapeutic 
target for the management of Th17-dominant CRSwNP 
patients in China [17].
Further understanding of the immunopathologic fea-
tures of CRS in Asian populations will be of great value 
to elucidate the pathogenesis of CRS. In this study, we 
aimed to investigate the expression of key transcription 
factors for Treg and Th1/Th2/Th17 cells, in relation to 
the mRNA expression of representative cytokines, in 
ECRS and non-ECRS subgroups.
Patients and methods
Patients
The diagnosis of CRSwNP was based on the criteria of 
the EAACI position paper [1], which defined it as having 
two or more of the following symptoms: blockage/con-
gestion, discharge, anterior/posterior drip, facial pain/
pressure, reduction or loss of smell for at least 3 months 
and endoscopic signs of nasal polyp(s). Patients with 
CRSwNP associated with chronic obstructive pulmonary 
disease, diffuse panbronchiolitis, Churg-Strauss Syn-
drome, congenital mucociliary diseases or cystic fibro-
sis were excluded from this study. None of the patients 
included had been treated with systemic corticosteroids 
or other immune-modulating drugs for at least 1 month 
prior to surgery, although some patients had received 
antihistaminic agents and/or macrolide antibiotics.
Patients were classified into two groups: the ECRS 
group, which was defined as having an eosinophil count 
of more than 50 per microscopic field (×400 magnifica-
tion) using five fields located in the subepithelial area of 
the polyps [4], and the non-ECRS group, which did not 
fulfill this criteria. The normal-appearing mucosa of the 
uncinate processes, which were surgically removed in 
eight patients without CRS (three with frontal sinus cysts, 
five with maxillary sinus tumors) served as the non-CRS 
control group. The study was approved by the ethical 
committee of The University of Tokyo Hospital (#2656). 
Informed consent was obtained from each patient before 
collecting samples.
Sampling of tissue specimens and histological procedures
The nasal polyps and control mucosae were harvested 
during endoscopic sinus surgery. A part of each sample 
was fixed in 10  % formalin, embedded in paraffin, sec-
tioned at 4  μm-thick, mounted on MAS-coated slides 
(Matsunami Glass, Osaka Japan) and used for hematox-
ylin-eosin staining as well as for immunohistochemistry. 
The remaining part was immediately immersed in RNA 
later® (Life Technologies, Carlsbad, CA, USA) and used 
for real time PCR analysis. Unfortunately we were unable 
to harvest enough mucosal tissue in some cases and were 
therefore unable to carry out some RT-PCR analyses in 
these cases (see Results and Table 1).
Immunohistochemistry
The following primary antibodies were used for identify-
ing inflammatory cells in the specimens: anti-CD3 (rabbit 
monoclonal, clone SP7; Nichirei, Tokyo, Japan), anti-CD4 
(rabbit monoclonal, clone SP35; Acris Antibodies Inc, 
San Diego, California, USA), anti-CD8 (mouse monoclo-
nal, clone C8/144B; Nichirei), and anti-FOXP3 (mouse 
monoclonal, clone 236A/E7; Abcam, Tokyo, Japan).
Sections rehydrated through a xylene and ethanol 
series were immersed in 10  mM citrate buffer solu-
tion (pH6.0, Dako Cytomation Japan, Kyoto, Japan) 
and autoclaved at 121  °C for 20 min for the retrieval of 
antigens. Endogenous peroxidase activity was blocked 
by treatment with 10  % hydrogen peroxide in metha-
nol for 15 min at RT. Next, sections were incubated for 
30  min in a blocking solution (PBS, pH 7.4, containing 
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2 % bovine serum albumin (Sigma-Aldrich Japan), 0.1 % 
Triton X-100, and 0.1  % sodium azide) at RT to reduce 
nonspecific antibody binding, then incubated with: anti-
CD3 antibody (1:400 in blocking solution), anti-CD4 
antibody (1:100 in blocking solution), anti-CD8 antibody 
(1:100 in blocking solution) and anti-FOXP3 antibody 
(1:100 in blocking solution) overnight at 4 °C. These anti-
gen retrieval and incubation conditions were determined 
based on the results of preliminary experiments (data not 
shown). After several washes in PBS (pH 7.4), sections 
were incubated for 30  min at RT with horseradish per-
oxidase (HRP) conjugated with anti-mouse or rabbit IgG 
antibodies (Simplestain MAX-PO, (M) and (R), ready-to-
use; Nichirei, Tokyo, Japan) corresponding to the primary 
antibodies. After more washes with PBS (pH 7.4), immu-
noreactivity was made visible with diaminobenzidine 
(DAB) (Simplestain DAB, ready-to-use; Nichirei). After 
washing with distilled water, the sections were counter-
stained with hematoxylin, then dehydrated and mounted. 
To ensure that there was no non-specific staining of pri-
mary antibodies, the primary antibodies were omitted 
from the reaction.
Cell counting
To determine the degree of eosinophil infiltration in 
the tissues, two of the authors independently manually 
counted the number of infiltrated cells in five random 
fields using H-E stained sections under light microscopy 
at high magnification (×400) in a blinded manner. The 
numbers of T cells, CD4+ T cells, CD8+ T cells and Treg 
were counted in the same manner using sections that 
were immunostained for each cell type.
Real‑time quantitative PCR analysis
The sample tissues were lysed in ISOGEN (Nippon Gene, 
Tokyo, Japan) and the total RNA was extracted according 
to the manufacturer’s instructions. The mRNA expres-
sion was analyzed using an Applied Biosystems 7500 
Real Time PCR System (PE Applied Biosystems, Fos-
ter City, CA, USA). The primers and probes for human 
β-actin, IL-4, 5, 13 and IL-4 receptor were designed by PE 
Applied Biosystems and their mRNA expression analysed 
using the TaqMan detection system. The mRNA of the 
transcription factors FOXP3, GATA3, T-bet, and RORc 
and cytokines IL-10, IL-17A, TGF-β1, and IFN-γ were 
analyzed using the SYBR Green detection system. The 
primers and probes for these transcription factors and 
cytokines were designed by SABiosciences (Hilden, Ger-
many). Nuclease-free water was substituted for cDNA in 
negative controls.
For relative quantification, data were analyzed by 
the ΔΔCt method and normalized to the average of 
Table 1 The number of inflammatory cells, expression of cytokines and transcription factors in normalized relative quan-
tities (NRQ), described as median (IQR) in the tissue of nasal polyps of ECRS and non-ECRS patients, and normal controls















Median (IQR) Median (IQR) Median (IQR) P‑value P‑value P‑value P‑value
The number of inflammatory cells
 Eosinophils 127.4 (81.4–180.7) 2.5 (0.55–7.3) 0 (0–0.05) <0.001 <0.001 <0.001 0.0082
 T cells (CD3) 29.8 (27.7–72.1) 60.5 (34.6–113.0) 56.2 (37.1–66.3) 0.34 0.52 0.14 0.74
 CD4+ cells 3.4 (2.3–7.3) 16.4 (10.0–24.2) 13.3 (10.3–16.5) 0.0016 0.005 0.0014 0.42
 CD8+ cells 36.6 (16.2–56.1) 63.2 (42.9–82.1) 34.4 (23.4–58.0) 0.029 0.67 0.022 0.038
mRNA expression of transcription factors
 Tbet 0.85 (0.5–1.4) 2.5 (1.2–113.2) 1.7 (1.1–2.7) 0.06 0.17 0.03 0.28
 GATA3 0.56 (0.33–0.73) 1.2 (0.54–39.9) 1.0 (0.9–1.9) 0.018 0.003 0.0049 0.92
 FOXP3 2.3 (1.9–3.2) 10.0 (6.2–30.8) 2.1 (1.0–4.5) <0.001 1 <0.001 0.005
 RORc 0.37 (0.096–0.49) 0.66 (0.48–10.9) 1.1 (0.91–1.56) 0.007 0.0025 0.0023 0.56
mRNAexpression of key cytokines
 IFN-γ 0.77 (0.28–1.2) 5.2 (1.4–16.4) 1.4 (0.81–2.2) 0.003 0.25 0.0015 0.04
 IL-5 137.8 (21.3–573.5) 0.11 (0.0–1.1) 0.39 (0.069–1.0) <0.001 <0.001 <0.001 0.88
 IL-13 16.5 (3.9–61.3) 0.3 (0.0–4.5) 0.81 (0.11–3.6) <0.001 0.006 <0.001 0.67
 IL-4 0.62 (0.19–0.98) 0.3 (0.095–0.89) 0.78 (0.17–1.3) 0.58 0.79 0.39 0.38
 IL-4R 0.052 (0.036–0.88) 0.11 (0.067–0.27) 0.24 (0.11–0.67) <0.001 <0.001 0.03 0.04
 IL-10 5.3 (2.5–8.1) 8.9 (4.0–268.4) 1.0 (0.93–2.4) 0.005 0.04 0.13 0.002
 TGF-β1 2.9 (1.9–4.0) 6.1 (3.6–17.6) 2.4 (1.5–2.9) 0.007 0.28 0.02 0.005
 IL-17 4.1 (1.3–12.3) 22.0 (8.3–4534.0) 4.0 (1.6–8.2) 0.042 0.92 0.03 0.03
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housekeeping genes such as β-actin (ACTB) in the 
TaqMan detection system and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) [18] in the SYBR Green 
detection system. For each sample using the TaqMan 
detection system, the differences in threshold cycles 
between the cytokine and β-actin or GAPDH genes (ΔCt 
sample, ΔCt control) were determined, and a calibrated 
ΔCt value (ΔΔCt, ΔCt sample − ΔCt control) was calcu-
lated. Samples using the SYBR Green detection system 
were normalized to the average of the housekeeping gene 
GAPDH. Then the relative quantitation (RQ) values were 
calculated using the following equation: RQ = 2−�∆Ct.
Statistical analyses
Statistical analyses were carried out using SPSS statistical 
software (SPSS, Chicago, IL, USA). All data are expressed 
as mean ± standard error in each group. When compari-
sons were made between groups, the Kruskal–Wallis test 
was used to assess significant intergroup variability. The 
significance of the difference between groups was deter-
mined using the Mann–Whitney U test. A difference was 
considered significant if p < 0.05.
Results
Patient profiles
The ECRS group included 15 male patients (age range 
42–76 years, mean age 58.3 years), in which the average 
eosinophil count in the total white cell count in periph-
eral blood was 6.8 % (range 3.1–12.8 %) and the average 
number of eosinophils was 399.0/mm3 (range 210.8–
625.6/mm3). Seven patients in this group had allergic 
rhinitis, one had asthma, while eight reported no allergy-
related diseases. All twelve of the female ECRS patients 
identified on the hospital database has used topical or 
oral steroids within a month prior to surgery and there-
fore had to be excluded from the present study.
The non-ECRS group included 16 patients (5 
females and 11 males, age range 40–70  years, mean 
age 57.6  years), in which the average eosinophil/total 
white cell count in peripheral blood was 1.9  % (range 
0.4–5.2  %) and the average number of eosinophils 
was 121.4/mm3 (range 40.0–260.0/mm3). Thirteen 
of these patients did not have any allergy-related dis-
eases, while the other three had allergic rhinitis. No 
patients in the non-ECRS group had asthma or aspirin 
sensitivity. The non-CRS group included 8 patients (3 
females and 5 males, age range 30–69 years, mean age 
52.6  years), in which the average eosinophil count in 
the total white cell count in peripheral blood was 2.2 % 
(range 1.0–3.7  %) and the average eosinophil number 
was 126.5/mm3 (range 50.0–210.9/mm3). Six of these 
patients did not have any allergy-related diseases while 
two had allergic rhinitis. No patients in the non-CRS 
group had asthma or aspirin sensitivity. There was 
no significant difference in age among three groups, 
whereas the peripheral blood eosinophil count was sig-
nificantly greater (p < 0.001) in the ECRS group com-
pared with the non-ECRS group and non-CRS control 
group. The patient profiles are shown in Table 2.
Histological observations of the nasal polyps showed 
that eosinophils were the predominant type of infil-
trating cell in the ECRS group (Fig.  1a). On the other 
hand, most of the infiltrating cells were lymphocytes 
and plasma cells in the non-ECRS group (Fig.  1b) 
while there were few infiltrating inflammatory cells in 
the non-CRS group (Fig.  1c). We identified the type 
of inflammatory cell based on their morphology in 
H-E stained sections. The pattern of inflammatory cell 
infiltration in the non-ECRS group was similar to that 
reported in our previous study in which an increased 
number of B cells and plasma cells was demonstrated 
by using immunohistochemistry for cell-type-specific 
markers [19].
Immunohistochemical analysis of inflammatory cells 
in nasal tissues
The number of eosinophils and cells positive for CD3 
(T-cells), CD4 and CD8 were counted using H-E and 
immunohistochemical staining in ECRS polyps, non-
ECRS polyps and non-CRS controls. Typical photo-
micrographs of immunohistochemically stained nasal 
tissue are shown in Fig.  2. As illustrated in Table  1, 
the median and interquartile range counts for eosino-
phils were significantly higher in ECRS polyps (n = 15, 
median 127.6; range 53.2-385.2) compared with 
non-CRS controls (n  =  8, median 0.0; range 0.0–3.8; 
p < 0.001) and non-ECRS polyps (n = 16, median 2.5; 
range 0.0–47.8; p  <  0.001) (Table  1). The number of 
eosinophils in polyps had a significant correlation 
with the number of blood eosinophils in both ECRS 
and non ECRS polyps (n = 31, r = 1.4311, p < 0.0001; 
Fig. 3).
As we have previously reported [20], the median 
counts for CD4+ T cells and CD8+ T cells were signifi-
cantly higher in non-ECRS polyps (n = 15, CD4: median 
16.4; range 0–43.4, CD8: median 63.2; range 28.8–155.8) 
compared with ECRS polyps (n = 12, CD4: median 3.4; 
range 1.2–16.4; p < 0.005, CD8: median 36.6; range 8.4–
91.4; p < 0.005) (Fig. 4b, c; Table 1). Moreover, there were 
significantly fewer CD4+ T cells in ECRS polyps than in 
non-CRS controls (n = 7, CD4: median 13.3; range 7.8–
21.3; p < 0.01). No significant difference was observed in 
the median count for T-cells among the groups (p > 0.05) 
(Fig. 4a; Table 1).
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Immunohistochemical localization of FOXP3
Representative microphotographs of non-ECRS polyps 
immunostained for FOXP3 are shown in Fig. 2b. FOXP3 
was localized in cells in the subepithelial layer, cells 
around the capillary vessels and cells in the lymphoid fol-
licles of ECRS and non-ECRS polyps.
Tissue expression of Treg and Th1/Th2/Th17‑ transcription 
factors
The expression levels of key transcription factors for Treg 
(FOXP3), Th1 (T-bet), Th2 (GATA3), and Th17 (RORc) 
were directly analyzed on tissue biopsies by means of quan-
titative real-time PCR. This revealed a significantly lower 
GATA3 mRNA expression level in ECRS polyps (n = 10) 
compared with non-ECRS polyps (n =  10, p  <  0.05) and 
controls (n = 7, p < 0.005) (Fig. 5b; Table 1). The expression 
of RORc was significantly lower in ECRS polyps (n = 10) 
compared with non-ECRS polyps (n =  10, p  <  0.05) and 
controls (n = 7, p < 0.005) (Fig. 5d; Table 1). T-bet was not 
significantly different between non-ECRS polyps (n = 10) 
and controls (n = 7), but was significantly higher in non-
ECRS compared with ECRS polyps (n  =  10, p  <  0.05) 
(Fig. 5a; Table 1). Moreover, in non-ECRS polyps (n = 10), 
FOXP3 mRNA expression was higher compared with con-
trols (n = 7, p < 0.01), and significantly higher compared 
with ECRS polyps (n = 10, p < 0.001) (Fig. 5c; Table 1).
Treg‑ and Th1/Th2/Th17‑related cytokine expression
Differences in Th1/Th2/Th17 cytokine patterns and Treg 
related TGF-β1/IL-10 were assessed at the mRNA level in 
ECRS polyps, non-ECRS polyps, and controls (Table 1). 
In ECRS polyps (n =  15), we found significantly higher 
mRNA expression of the Th2 cytokine IL-5 compared 
with controls (n = 8, p < 0.001) and with non-ECRS pol-
yps (n = 13, p < 0.001) and a significantly higher mRNA 
expression of IL-13 in ECRS polyps (n =  15) compared 
with controls (n = 8, p < 0.01) and with non-ECRS polyps 
(n =  16, p  <  0.001). For IL-4, no significant differences 
were noted among controls, ECRS, and non-ECRS pol-
yps. Conversely, mRNA levels of IL-4 receptor (the com-
mon receptor of IL-4 and IL-13) were significantly lower 
in ECRS polyps (n = 14) compared with controls (n = 8, 
p < 0.05) and with non-ECRS polyps (n = 14, p < 0.05). 
In contrast, mRNA levels of the Th1 cytokine IFN-γ were 
significantly higher in non-ECRS polyps (n =  12) com-
pared with controls (n = 6, p < 0.05) and with ECRS pol-
yps (n = 10, p < 0.005). mRNA expression of TGF-β1 was 
significantly higher in non-ECRS polyps (n =  10) com-
pared with controls (n  =  7, p  <  0.005) and with ECRS 
polyps (n = 10, p < 0.05). mRNA expression of IL-10 was 
significantly higher in non-ECRS polyps (n =  12) com-
pared with controls (n  =  7, p  <  0.005). Furthermore, 
IL-10 mRNA levels were significantly lower in ECRS 
Table 2 Patient profiles
a Data are expressed as means and ranges
b Data are expressed as medians and ranges
Patient group Number (n) Male:female Age (years)a Asthma Allergic rhinitis Eosinophil count in the 
total white cell count (%)a
Eosinophil count in nasal 
tissuesb
ECRS 15 15:0 58.3 (42–76) 1/15 7/15 6.8 (3.1–12.8) 127.6 (53.2–385.2)
Non-ECRS 16 11:5 57.6 (40–70) 0/16 3/16 1.9 (0.4–5.2) 2.5 (0–47.8)
Non-CRS 8 5:3 52.6 (30–69) 0/8 2/8 2.2 (1.0–3.7) 0.0 (0–3.8)
Fig. 1 Representative H-E-stained histological sections of nasal polyps (a, b) and uncinate process mucosa (c) obtained from ECRS (a), non-ECRS (b) 
and non-CRS (c) groups. In the ECRS group, almost all of the infiltrating cells are eosinophils (a), whereas most of the infiltrating cells are lympho-
cytes (black arrows) and plasma cells (red arrows) in the non-ECRS group (b). Few inflammatory cells are infiltrating in non-CRS group (c). Scale bar 
100 μm
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polyps compared with controls (p  <  0.05). The mRNA 
expression of IL-17A was significantly higher in non-
ECRS polyps (n  =  10) compared with controls (n  =  7, 
p < 0.05) and with ECRS polyps (n = 10, p < 0.05).
Discussion
In this study, we analyzed the expression of the tran-
scription factors FOXP3, T-bet, GATA3, and RORc in 
relation to Treg and Th1/Th2/Th17-related cytokines in 
the sinonasal mucosal tissue of ECRS polyps, non-ECRS 
polyps and non-CRS controls. We demonstrated a sig-
nificantly lower mRNA expression of RORc in ECRS 
polyps compared with non-ECRS polyps and non-CRS 
controls in the Japanese population, indicating the reduc-
tion of Th17 effector cells in ECRS. Unexpectedly, we 
also found a significantly lower mRNA expression of 
GATA3 in ECRS polyps. In addition, we observed an 
increase in mRNA expression of FOXP3 in non-ECRS 
polyps compared with ECRS polyps and controls, and 
an increase in mRNA expression of T-bet in non-ECRS 
polyps compared with ECRS polyps, suggesting upregu-
lation of Th1 and Treg cells in non-ECRS polyps. To the 
best of our knowledge, this report is the first to examine 
T-cell signature transcription factors and cytokines in 
nasal polyps comparing ECRS and non-ECRS in an Asian 
population.
Increased IL-17A has been proposed as being respon-
sible for enhanced tissue neutrophilia, collagen deposi-
tion and corticosteroid resistance in polyp tissues [21, 22]. 
Furthermore, in vitro studies have shown that the induc-
tion of metalloproteinases by IL-17, which can lead to 
the characteristic edema formation in the nasal polyps of 
patients with cystic fibrosis, is characterized by abundant 
neutrophils and increased concentrations of IL-8 and 
MPO [23]. In addition to Th17 cells, other cell types also 
express IL-17 [24, 25]. CD8+ T cells, γδ T cells, invari-
ant natural killer T cells, and lymphoid tissue inducer-like 
cells have all been found to express and produce IL-17 
[24]. Treg cells can produce IL-17 when they are strongly 
activated in the presence of proinflammatory cytokines, 
Fig. 2 Photomicrographs showing immunohistochemical staining for CD3 (T-cells; a), FOXP3 (b), CD4 (c) and CD8 (d) in non-ECRS polyps. Scale bar 
100 μm
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such as IL-1β and IL-6 [25]. Therefore, increased IL-17A 
expression does not directly support the effect of Th17 
cells. However, IL-17A and IL-17F are expressed most 
abundantly by Th17 cells [25]. In this study we demon-
strated increased IL-17A mRNA expression in non-ECRS 
tissue. This finding, together with the upregulation of 
RORc, suggests a role of Th17 cells in the pathogenesis of 
non-ECRS.
Due to the absence or low expression of IL-17A in 
polyp tissues in western patients [26], Th17 cells have not 
been well documented in the pathogenesis of CRSwNP. 
Recently, some studies have demonstrated that Th17 
cells are specifically increased in nasal polyp patients in 
China and eastern Asian regions compared to their west-
ern counterparts [17, 27]. Our results regarding Treg/
Th1 ⁄ Th2 ⁄Th17 signature transcription factor profiles 
Fig. 3 Correlation between the number of eosinophils in polyps and the number of blood eosinophils in the ECRS group (red squares) and non-
ECRS group (blue diamonds)
Fig. 4 The number of inflammatory cells in mucosal specimens. The number of CD3 positive cells (T cells) (a), CD4 positive cells (b) and CD8 posi-
tive cells (c) per field in the ECRS and non-ECRS polyps, as well as the non-CRS controls. Data in box-and-whisker plots represent the median, lower 
and upper quartile and the minimum to maximum value. ×, outliers (†p < 0.005, **p < 0.01, *p < 0.05)
Page 8 of 11Baba et al. Allergy Asthma Clin Immunol  (2015) 11:33 
and IL-17 are partially discrepant from these findings. 
Zhang et al. [27] demonstrated that although IL-17 levels 
were obviously upregulated in nasal polyps from Chinese 
patients, RORc expression was not significantly different 
between patients and controls. Shen et al. [28] reported 
an increase in Th17 and a decrease in Treg in non-ECRS 
patients in China. Conversely, Li et  al. [29] found that 
Th17 (RORc) and Th2 (GATA3) were downregulated and 
that Treg (FOXP3) was increased in non-ECRS patients 
in China. Meanwhile, Van Bruaene et  al. [12] reported 
that for IL-17 and RORc expression in polyp tissue, no 
significant differences were noted between European 
patients and controls. We presume that these contradic-
tory observations might be attributed to different eth-
nic groups and variations in the clinical severity of NP 
patients.
TGF-β1 induces FOXP3 expression in CD25- naive T 
cells to enforce transition to Treg cells and is a critical 
Fig. 5 mRNA expression of transcription factors (T-bet, GATA-3 FOXP3, RORc) involved in naive T-cell differentiation in ECRS, non-ECRS and non-CRS 
controls. The box represents the distribution of values; the line across the box represents the median; the box stretches from the lower hinge (the 
25th percentile) to the upper hinge (the 75th percentile). ×, outliers (††p < 0.001, †p < 0.005, *p < 0.05)
Page 9 of 11Baba et al. Allergy Asthma Clin Immunol  (2015) 11:33 
factor in the development of peripheral Treg cells [30]. 
We found a significant upregulation of TGF-β1 at the 
mRNA level in non-ECRS polyps compared with ECRS 
polyps and controls. Furthermore, high TGF-β1 mRNA 
levels coincided with adequate FOXP3 expression in 
non-ECRS tissue, implying a functional link. The effect 
of local TGF-β1 on Treg function has to be confirmed 
in non-ECRS tissue. In contrast, there was no significant 
difference in TGF-β1 mRNA expression in ECRS tissue 
versus controls.
IL-10, a cytokine that is intimately involved in the 
regulation of inflammatory and immune responses, was 
measured at the mRNA level. The induction of periph-
eral regulatory T cells by IL-10 points toward a crucial 
role in the establishment of peripheral tolerance [31]. 
Specifically, IL-10 is instrumental in Treg-mediated 
suppression of proliferation and cytokine production of 
naive CD4+ CD25-T, Th1, and Th2 cells. Activation of T 
cells in the presence of IL-10 induces a long-lasting state 
of nonresponsiveness or anergy [32]. Here, we found 
a significant upregulation of IL-10 at the mRNA level 
in non-ECRS tissue compared with controls, whereas 
IL-10 mRNA was downregulated in ECRS patients com-
pared with controls. TGF-β and IL-10 are both suppres-
sor cytokines that frequently occur together at sites of 
inflammation, and both cytokines cooperate in the res-
olution of inflammation. TGF-β can induce IL-10 pro-
duction, and IL-10 facilitates TGF-β regulatory activity 
[33]. The striking coincidence of low IL-10 RNA levels, 
together with basal levels of TGF-β1 mRNA (not raised 
compared with controls) in ECRS tissue, points to the 
lack of a regulatory effect in the resolution of inflam-
mation, hence contributing to the chronicity of this 
disease.
T-bet is a Th1-specific T-box transcription factor that 
controls the expression of the hallmark Th1-cytokine 
IFN-γ, and T-bet expression correlates with IFN-γ 
expression in Th1 cells [6]. We report an increase in 
mRNA expression of IFN-γ in non-ECRS compared with 
ECRS tissues and controls and an increase in mRNA 
expression of T-bet in non-ECRS compared with ECRS 
tissues. Different from T-bet, the expression of which is 
mainly restricted to the Th1 cell type, IFN-γ can be pro-
duced by several cell types including CD4+ Th1 cells, 
CD8+ cells, and natural killer cells, but also B cells [6]. 
In this study, CD4+ and CD8+ T-cell levels were signifi-
cantly decreased in ECRS patients compared with non-
ECRS patients. Additionally, we have previously reported 
an increased number of plasma cells and increased 
expression of IgG mature transcripts in the same non-
ECRS patients [19]. These data indicate that IFN-γ may 
contribute to the development of chronic inflammation 
in patients with non-ECRS.
The present study demonstrated significantly elevated 
IL-5 and IL-13 levels in ECRS polyps, although CD4+ 
cells and expression of Th2 signature transcription factor 
GATA3 mRNA were decreased. This was the most sur-
prising result in our analysis and is difficult to interpret. 
The most straightforward explanation for lower GATA3 
expression would be the decreased number of Th2 cells. 
However, the regulation of gene expression is a complex 
process, and both GATA3 and Th2 cytokines, originally 
regarded as indicators of Th2 cells, are actually expressed 
in other inflammatory cell types [34]. Therefore, the 
mRNA expression of GATA3 alone does not lead to any 
conclusion as to the number or activity of Th2 cells.
The expression of GATA3 mRNA in nasal polyps 
reported previously varies from paper to paper. In a 
Chinese population, Li et  al. [29] reported that GATA3 
mRNA expression was downregulated in polyp tissue, 
while Zhang et al. [27] reported that GATA3 expression 
in polyp tissue was not significantly different compared 
to controls. Conversely, Shi et al. [11] demonstrated that 
GATA3 expression was obviously upregulated in nasal 
polyps compared with the controls in a Chinese popula-
tion. As for the western population, Van Bruaene et  al. 
[12] reported that GATA3 expression was obviously 
upregulated in nasal polyps compared with controls and 
tissue from CRS patients without nasal polyps. Zhang 
et  al. [27] also found GATA3 expression was upregu-
lated in nasal polyps in a Belgian population. On the 
other hand, Miljkovic et al. [35] reported downregulated 
mRNA expression of GATA3 in nasal polyps from west-
ern patients compared with controls.
In our study, if we simply compared CRSwNP patients 
(which includes both ECRS and non-ECRS patients, 
n  =  20) and controls, there was no significant differ-
ence in GATA3 expression between them (p  =  0.11). 
The divergent data regarding GATA3 mRNA expression 
among these studies may therefore be more associated 
with the way patients were selected and categorized and 
less so with their ethnic background or variations in their 
clinical severity.
One explanation for the upregulation of Th2 cytokine 
in spite of decreased GATA3 expression may be an 
involvement of Group 2 innate lymphoid cells (ILC2s). 
Innate lymphoid cells (ILCs) are a heterogeneous group 
of cell types that play a role in innate immune responses 
and tissue remodeling at mucosal barrier surfaces. They 
are functionally related to T helper subsets, mirroring 
the production of specific T helper cytokines and hav-
ing a lymphoid morphology. A subset of ILCs, termed 
group 2 ILCs (ILC2s), was recently identified in human 
nasal tissues [36, 37], and have been implicated in the ini-
tiation and coordination of Th2-type immune responses 
[38] and shown to produce the cytokines IL-5, IL-6, IL-9 
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and IL-13 [36, 38]. Very recently, Miljkovic et al. reported 
an upregulation of IL-5 and IL-13 mRNA levels and 
diminished mRNA expression of IL-25 and GATA3 in 
CRSwNP [35]. They also found that ILC2 s were signifi-
cantly enriched in nasal polyp (CRSwNP) patients [35]. 
Moreover, Klein Wolterink et  al. showed that the novel 
population of ILC2 surprisingly constitutes an impor-
tant fraction of IL-5 and IL-13 cytokine producing cells, 
next to the classical Th2 cells, in allergen-induced allergic 
asthma in mice [39]. Therefore, ILC2 might be a major 
source of IL-5 and IL-13 instead of Th2 in ECRS pol-
yps. Further research into the sources of Th2-inducing 
cytokines is warranted.
Our results demonstrate that regardless of the dif-
ferent T cell inflammatory patterns, both ECRS and 
non-ECRS patients showed the same overgrowth of 
nasal mucosa that characterizes CRSwNP patients. 
It may therefore be speculated that CRSwNP is not a 
simple, helper T cell-derived inflammatory disease, 
but involves other as yet unspecified pathological pro-
cesses, such as impaired remodeling processes. With 
this possibility in mind, it may be necessary to develop 
an additional strategy to investigate the pathogenesis of 
nasal polyposis.
Conclusion
Our findings show a reduction of GATA3 and RORc 
mRNA, low Treg-related cytokines and elevated Th2 
cytokine levels in ECRS patients. In contrast, we demon-
strated the upregulation of FOXP3 and RORc mRNA and 
increases of Treg, Th1 and Th17 cytokines in non-ECRS 
patients. This heterogeneity of immunological profiles in 
Japanese CRS patients suggests that the pathogenesis of 
nasal polyps in the Japanese population is not identical to 
that of nasal polyposis in Western patients, a fact which 
may be helpful in the development of novel therapeutic 
strategies.
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